2024
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart review
2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatmentSentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.Peer-Reviewed Original ResearchConceptsAcral lentiginous melanomaNational Cancer DatabaseClinical stage IBSLN positivityStage IBSentinel lymphCutaneous melanomaPositivity rateMalignant melanomaHigh riskSentinel lymph node statusAJCC Cancer Staging ManualClinical stage IRetrospective cohort studySignificant prognostic factorsLymph node statusCancer Staging ManualMultivariable logistic regressionHigher positivity rateAJCC clinical stageCohort studySLN statusPrognostic factorsSuch patientsStaging Manual
2021
A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis
Cheraghlou S, Sadda P, Agogo GO, Girardi M. A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis. Australasian Journal Of Dermatology 2021, 62: 323-330. PMID: 34028790, DOI: 10.1111/ajd.13624.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMerkel cell carcinomaPositive lymph node countLymph node countPositive nodesDistant metastasisValidation cohortRare neuroendocrine skin cancerRetrospective cohort studyEnd Results registryLymph node biopsyLymph node metastasisThree-year survivalNeuroendocrine skin cancerNovel prognostic factorHigh mortality rateNode countAJCC groupsMCC stagingSEER cohortCohort studyMCC patientsNode biopsyPrognostic factorsNode metastasisAssociation of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma
Cheraghlou S, Christensen SR, Leffell DJ, Girardi M. Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma. JAMA Dermatology 2021, 157: 531-539. PMID: 33787836, PMCID: PMC8014201, DOI: 10.1001/jamadermatol.2021.0023.Peer-Reviewed Original ResearchConceptsMohs micrographic surgeryNational Cancer DatabaseTreatment facility characteristicsMicrographic surgeryInvasive melanomaCohort studyOverall survivalImproved long-term survivalLong-term patient survivalCox proportional hazards modelFacility characteristicsCancer-accredited facilitiesStudy of resectionRetrospective cohort studyMultivariable survival analysisWide local excisionHazard of deathTreatment of patientsLow-volume facilitiesProportional hazards modelEarly-stage melanomaFacility-level factorsLong-term survivalImproved survivalLocal excisionThe PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAgedAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleFemaleFollow-Up StudiesGelsHumansMaleMechlorethamineMiddle AgedMycosis FungoidesNeoplasm StagingProspective StudiesQuality of LifeSeverity of Illness IndexSkin NeoplasmsTreatment OutcomeUnited StatesConceptsHealth-related qualityMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaChlormethine gelT-cell lymphomaMechlorethamine gelMonths post-treatment initiationEfficacy-evaluable patientsSkin-directed therapiesPrimary efficacy endpointProportion of patientsPatient-completed questionnairesPost-treatment initiationSkindex-29 scoresImportant therapeutic optionBody surface areaSkindex-29 questionnaireAssessment of responseReal-world studyPROVE StudyEfficacy endpointTopical corticosteroidsAdult patientsClinic visitsMycosis fungoides
2020
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementLow-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesLocal immunotherapyIntralesional injectionSide effectsAssociated systemic side effectsSkin-homing T cellsEarly-stage mycosis fungoidesTreatment of MFCases of MFGeneralized side effectsStage mycosis fungoidesT-cell lymphomaSystemic side effectsRecombinant interferon α2bImprovement of diseaseSystemic therapyRecalcitrant lesionsMF patientsTherapeutic optionsMalignant CD4Intramuscular injectionMF lesionsSystemic administrationSubsequent dosingReal-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study
Kim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, Mink DR, Williams MJ, Angello JT, Bailey WL. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal Of The American Academy Of Dermatology 2020, 83: 928-930. PMID: 32089294, DOI: 10.1016/j.jaad.2019.12.070.Peer-Reviewed Original Research
2019
Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma
Cheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatology 2019, 155: 803-811. PMID: 30825411, PMCID: PMC6583886, DOI: 10.1001/jamadermatol.2019.0267.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMerkel cell carcinomaPositive lymph nodesDisease-specific survivalLymph nodesSEER registryEligible casesPatient survivalPatient counselingCell carcinomaPrognostic indicatorPopulation-based US cohortLong-term patient survivalAJCC N stagingCancer-accredited facilitiesAdjuvant radiation therapyRetrospective cohort studyAdjuvant chemoradiation therapyEnd Results registryTreatment planningHigh mortality rateSEER data setLNR statusTraditional TNMAdjuvant therapyEffect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration
2018
Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival
Cheraghlou S, Agogo GO, Girardi M. Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival. Journal Of The American Academy Of Dermatology 2018, 80: 979-989. PMID: 30365997, DOI: 10.1016/j.jaad.2018.10.026.Peer-Reviewed Original ResearchConceptsLong-term patient survivalImproved long-term patient survivalHigh-volume centersPatient survivalCase volumeNonmetastatic melanomasPatient outcomesTop quartileMiddle quartilesLong-term patient outcomesHigh-volume academic centersCenter case volumeFacility case volumeTreatment center characteristicsDisease-specific survivalNational Cancer DatabaseHigh-volume facilitiesCases of melanomaAcademic affiliationImproved survivalCancer careCancer DatabaseImproved outcomesUS adultsAcademic centersDisease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database
Su C, Tang R, Bai HX, Girardi M, Karakousis G, Zhang PJ, Xiao R, Zhang G. Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database. British Journal Of Haematology 2018, 185: 592-595. PMID: 30216417, DOI: 10.1111/bjh.15570.Peer-Reviewed Original ResearchClinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original ResearchPredicting non-melanoma skin cancer via a multi-parameterized artificial neural network
Roffman D, Hart G, Girardi M, Ko CJ, Deng J. Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network. Scientific Reports 2018, 8: 1701. PMID: 29374196, PMCID: PMC5786038, DOI: 10.1038/s41598-018-19907-9.Peer-Reviewed Original ResearchConceptsNon-melanoma skin cancerFamily historySkin cancerUVR exposureHistory of strokePotential predictive parametersNon-cancer casesFamily history informationUltraviolet radiation exposureDiabetic statusSmoking statusHeart diseaseRisk factorsExercise habitsHispanic ethnicityPredictive parametersAdult survey dataEarly detectionRadiation exposureROC curveHealth informationPersonal health informationNovel associationsCancerExposure
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategiesPrimary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.Peer-Reviewed Original ResearchAnnual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volumePrimary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas
Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Modern Pathology 2017, 30: 761-772. PMID: 28128277, PMCID: PMC5413429, DOI: 10.1038/modpathol.2016.240.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationCutaneous lymphomasT-cell lymphomaCell transplantationProvisional entityAggressive epidermotropic cytotoxic T-cell lymphomaEpidermotropic T-cell lymphomaPatch/plaque lesionsCytotoxic T-cell lymphomaWorld Health Organization classificationT cell receptor expressionLack of CD8Rare cutaneous lymphomaMucous membrane involvementInclusion of casesT cell receptor chainsComplete remissionMedian survivalStandard therapyMedian ageMycosis fungoidesPoor prognosisUlcerative lesionsOrganization classification
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1 therapyCutaneous adverse effectsPD-L1 therapyCell death 1Concurrent medicationsDeath-1Adverse effectsClinical morphologyAnti-PD-1/PD-L1 treatmentAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesAnti-programmed cell death 1Non-small cell lung cancerDeath ligand 1 (PD-L1) immunotherapyPD-L1 antibody therapyCell death ligand 1Yale-New Haven HospitalMucocutaneous adverse effectsPD-L1 treatmentTreatment of rashTertiary care hospitalDeath ligand 1Lichenoid drug eruptionCell lung cancerSkin biopsy specimensRecent US Food